k25. malaria pada anak.ppt
TRANSCRIPT
-
8/10/2019 K25. Malaria pada Anak.ppt
1/39
MALARIA IN CHILDREN
PREVENTION AND TREATMENT
Chairuddin P.Lubis
Department o f Chi ld Health
Medical School, Universi ty of Sumatera Utara
Medan, Ind onesia
-
8/10/2019 K25. Malaria pada Anak.ppt
2/39
BACKGROUND
Malaria is the worldsmost important parasitic infection (1)
and remains a major global public heath concern (2)
A long with tuberculosis and HIV infection, malaria forms a
disease triad that accounts for almost half of all infectious
disease mortality(3)
-
8/10/2019 K25. Malaria pada Anak.ppt
3/39
(1)
-
8/10/2019 K25. Malaria pada Anak.ppt
4/39
(2)
-
8/10/2019 K25. Malaria pada Anak.ppt
5/39
-
8/10/2019 K25. Malaria pada Anak.ppt
6/39
-
8/10/2019 K25. Malaria pada Anak.ppt
7/39
-
8/10/2019 K25. Malaria pada Anak.ppt
8/39
Malaria Rapid Diagnostic Tests (RDTs)
(3)
-
8/10/2019 K25. Malaria pada Anak.ppt
9/39
-
8/10/2019 K25. Malaria pada Anak.ppt
10/39
-
8/10/2019 K25. Malaria pada Anak.ppt
11/39
-
8/10/2019 K25. Malaria pada Anak.ppt
12/39
-
8/10/2019 K25. Malaria pada Anak.ppt
13/39
-
8/10/2019 K25. Malaria pada Anak.ppt
14/39
-
8/10/2019 K25. Malaria pada Anak.ppt
15/39
Prevention of Malaria3,11
1. Protection against Mosquito Bites
2. Using an insect repellent
3. Prophilactic Agents
The risk for acquiring malaria varies according to
geographic area, altitude, season, time of day, specific
setting (urban versus rural), duration of stay in an
endemic area, type of accomodation, and compliancewith preventive measure.
-
8/10/2019 K25. Malaria pada Anak.ppt
16/39
(4)
-
8/10/2019 K25. Malaria pada Anak.ppt
17/39
(6)
-
8/10/2019 K25. Malaria pada Anak.ppt
18/39
(6)
-
8/10/2019 K25. Malaria pada Anak.ppt
19/39
-
8/10/2019 K25. Malaria pada Anak.ppt
20/39
(6)
-
8/10/2019 K25. Malaria pada Anak.ppt
21/39
(6)
-
8/10/2019 K25. Malaria pada Anak.ppt
22/39
TREATMENT
Just i f icat ion:The first guidel ine on d iagnos is and management of
malar ia in chi ldren was formulated by Infect iou s Diseases Chapter of
IAP in 2005. In subsequent year WHO proposed artem isin in b asedcombinat ion therapy in al l cases of uncompl icated falciparum malar ia.
The number of falciparum malar ia as wel l as mult idrug resistant
fa lciparum malar ia cases are constant ly on the r ise. So there was need
to revise the exist ing guid eline.
Process:The f irs t recommendat ions on the diagnos is and
management of m alar ia in ch i ldren were form ulated in 2005. The same
pro toco l was revised on 12 Octob er 2007 in NIMHANS, Bangalore in
the l ight of var ious recommendations of WHO, where al l the members
of the Task Force Comm ittee on Malar ia in Chi ld ren were present.
Object ive: To revise and upd ate treatment guid el ines fo r m alar ia with
special reference to artemisin in based combinat ion th erapy.Recommendat ions:The need for Ar temis in in based combination
therapy (ACT) is emphasized in chlo roqu ine resistant falciparum
malar ia. Monotherapy w ith artesunate wi l l fur th er increase the
resistance. Once malar ia treatment is ini t iated it sh ou ld be com pleted.
In severe malar ia the maintenance dose o f artesunate is revised.
(7)
(7)
-
8/10/2019 K25. Malaria pada Anak.ppt
23/39
Drug sensitivity Recommended treatment
P. vivax and *Chloroquine 10 mg base/kg stat followed
by 5mg/kg at 6, 24 and 48 hours.
chloroquine sensitive OR
P. falciparum Chloroquine 10mg base/kg stat followed by
10mg/kg at 24 hours and 5mg/kg at 48
hours (total dose 25mg base/kg).
* In case of vivax malaria, to preventrelapse, primaquine should be given in a
dose of 0.25 mg/kg once daily for 14
days. In case of falciparum malaria, a
single dose of primaquine (0.75mg/kg) is
given for gametocytocidal action.
TABLE Ia RECOMMENDED TREATMENT IN CHLOROQUINESENSITIVE MALARIA
(7)
-
8/10/2019 K25. Malaria pada Anak.ppt
24/39
Chloroquine should not be given on an empty stomach and in
high fever. Bring down the temperature first. If vomiting occurs
within 45 minutes of a dose of chloroquine, that particular dose
is to be repeated after taking care of vomiting by usingantiemetic (domperidone/ondansetron).
According to National Anti Malarial Program, a 5 days course
of primaquine is advocated because of risk of toxicity and
operational feasibility. Whereas other authorities advocate 14days course of primaquine due to lack of evidence to support
shorter courses(7). As primaquine can cause hemolytic anemia
in children with G6PD deficiency, they should be preferably
screened for the same prior to starting treatment. As infants
are relatively G6PD deficient, it is not recommended in this age
group and children with 14 days regime should be under close
supervision to detect any complication. In cases of borderline
G6PD deficiency, once weekly dose of primaquine 0.60.8
mg/kg is given for 6 weeks.
-
8/10/2019 K25. Malaria pada Anak.ppt
25/39
TABLE Ib RECOMMENDED TREATMENT IN CHLOROQUINE
RESISTANT P. FALCIPARUM
Artesunate 4mg/kg of body weight once daily for 3 days anda single administration of SP as 25mg/kg of sulfadoxine and
1.25 mg/kg of pyrimethamine on day 1or artesunate as above
and mefloquine 25mg/kg of body weight in two (15 + 10)
divided doses on day 2 and day 3.OR
Co-formulated tablets containing 20 mg of artemether and 120
mg of lumefantrine can be used as a six dose regimen twice a
day for 3 days. For 5-14 kg body weight 1 tablet at diagnosis,again after 8 hours and then twice daily on day 2 and day 3.
For 15 to 24 kg body weight same schedule with 2 tablets. For
25-35 kg body weight and above same schedule with 3 and 4
tablets, respectively.
(7)
-
8/10/2019 K25. Malaria pada Anak.ppt
26/39
(i) Under the previous National Drug Policy, SP monotherapy
in a single dose was used in areas of chloroquine
resistance. Countries where SP was introduced following
CQ resistance showed its rapid decline in efficacy withinfew years.
(ii) Currently there are insufficient safety and tolerability data
on mefloquine at its recommended dosage of 25 mg/kg
body weight in children. Mefloquine shares cross resistancewith quinine which is still a effective drug in our country.
Health planners of our country do not advocate use of
menfloquine.
(iii) Advantage of artemether lumefantrine combination is that
lumefantrine is not available as monotherapy and has never
been used by itself for the treatment of malaria.
Lumefantrine absorption is enhanced by coadministration
with fatty food like milk.
TABLE I RECOMMENDED TREATMENT OF MULTIDRUG (7)
-
8/10/2019 K25. Malaria pada Anak.ppt
27/39
TABLE Ic: RECOMMENDED TREATMENT OF MULTIDRUG
RESISTANT P. FALCIPARUM (BOTH TO CHLOROQUINE AND
SULFADOXINEPYRIMETHAMINE)
Quinine, 10mg salt/kg/dose 3 times daily for 7 days.+
Tetracycline (above 8 years) 4mg/kg/dose 4 times daily for 7 days
OR
Doxycycline (above 8 years) 3.5mg/kg once a day for 7 days
OR
Clindamycin 20mg/kg/day in 2 divided doses for 7 days.In case of cinchonism,
Quinine, 10mg salt/kg/dose 3 times daily for 3-5 days
+
Tetracycline (above 8 years) 4mg/kg/dose 4 times daily for 7 days
OR
Doxycycline (above 8 years) 3.5mg/kg once a day for 7 daysOR
Clindamycin 20mg/kg/day in 2 divided doses for 7 days.
A single dose of primaquine above 1 year age (0.75mg/kg) is given for
gametocytocidal action.
OR
Artemether lumefantrine combination as in table 1b .
(7)
-
8/10/2019 K25. Malaria pada Anak.ppt
28/39
(i) Doxycycline is preferred to tetracycline as it can be givenonce daily and does not accumulate in renal failure.
(ii) One of the drawbacks of quinine therapy is its long course.
Unsupervised and ambulatory setting may decrease
patients compliance and many patients might not
complete the full course of prescribed therapy.
(iii) Fortunately children tolerate quinine better than adults.
-
8/10/2019 K25. Malaria pada Anak.ppt
29/39
TABLE Id RECOMMENDED TREATMENT IN FAILURE
WITH ARTEMISININ COMBINATION THERAPY (ACT)
Quinine + Tetracycline or Doxycycline or Clindamycin for 7 days as in Table Ic .
(i) Treatment failure within 14 days of receiving an ACT isunusual. It should be confirmed parasitologically by
blood slide examination. It is important to determine
whether patient has vomited previous treatment or did
not complete a full course.
(ii) Failure after 14 days of treatment can be re-treated with
first line ACT.
(7)
(7)
-
8/10/2019 K25. Malaria pada Anak.ppt
30/39
TABLE II DRUG AND DOSAGE OF ANTIMALARIALS IN
COMPLICATED AND SEVERE MALARIA
Drug Dosages(5,9)
Quinine salt 20mg salt/kg (loading dose) diluted in 10mL of isotonic
fluid/kg by infusion over 4 hours. Then 12 hours after
the start of loading dose give a maintenance dose of
10mg salt/kg over 2 hours. This maintenance dose
should be repeated every 8 hours, calculated from beginning of previous infusion, until the patient can
swallow, then quinine tablets, 10mg salt / kg 8 hourly to
complete a 7 day course of treatment (including both
parenteral and oral). Tetracycline or doxycycline or
clindamycin is added to quinine as soon as the patientis able to swallow and should be continued for 7 days.
Dosage as in table 1c. If controlled IV infusion cannot
be administered then quinine salt can be given in the
same dosages by IM injection in the anterior thigh (not
in buttock).
(7)
-
8/10/2019 K25. Malaria pada Anak.ppt
31/39
The dose of quinine should be divided between two sites,
half the dose in each anterior thigh. If possible IM quinine
should be diluted in normal saline to a concentration of 60-
100mg salt/ml. (Quinine is usually available as 300mg
salt/ml). Tetracycline or doxycycline or clindamycin should
be added as above.
Artesunate 2.4 mg/kg IV then at 12 and 24 hours, then once a day for
total 7 days. If the patient is able to swallow, then the daily
dose can be given orally. Tetracycline or doxycycline or
clindamycin is added to artesunate as soon as the patient
can swallow and should be continued for 7 days. Dosage
as in Tab le 1c.
OR
Artemether 3.2 mg/kg (loading dose) IM, followed by 1.6 mg/kg daily
for 6 days. If the patient is able to swallow, then the dailydose can be given orally. Tetracycline or doxycycline or
clindamycin is added to artemether as soon as the patient
can swallow and should be continued for 7 days. Dosage
as in Table 1c.
-
8/10/2019 K25. Malaria pada Anak.ppt
32/39
(i) Loading do se of quin ine shou ld not be used i f the pat ient has
received quinin e, qu inid ine or mefloquine within th e preceding
12 hours. Alternat ively, loading dos e can be admin istered as
7mg salt/kg by IV infusion pump over 30 m inutes, fol lowedimm ediately by 10mg salt /kg d i luted in 10 ml isoto nic f lu id/kg
by IV infus ion over 4 hours.
(i i) Quin ine shou ld not b e given by bolus or push in ject ion.
Infus ion rate shou ld no t exceed 5 mg salt /kg /hou r.
(i i i) If there is no cl in ical imp rovement after 48 hou rs o f parenteral
therapy, the maintenance dose of quin ine shou ld be reduc ed
by one third to one half i.e., 5-7 mg salt/kg.
(iv) Quin ine shou ld not b e given subcutaneously as th is may
cause skin necrosis.
(v) Previou s maintenance dose of parenteral artesun ate of 1.2
mg/kg has been modif ied by WHO to 2.4 mg/kg.
(v i) Artesunate, 60mg per ampoule is diss olved in 0.6mL o f 5%
sodium bicarbonate di lu ted to 35 mL with 5% dextrose and
given immediately by IV bolu s (push inject ion).
(v i i) Artemether is disp ensed in 1 mL ampoule conta in ing 80mg of
artemether in peanut o il .
(6)
-
8/10/2019 K25. Malaria pada Anak.ppt
33/39
(6)
(5)
-
8/10/2019 K25. Malaria pada Anak.ppt
34/39
(5)
-
8/10/2019 K25. Malaria pada Anak.ppt
35/39
(6)
-
8/10/2019 K25. Malaria pada Anak.ppt
36/39
(6)
-
8/10/2019 K25. Malaria pada Anak.ppt
37/39
Local cost and availability of antimalarial drugs.
Area of malaria acquisition (i.e. drug resistance
pattern of P. falciparum).
Prior chemoprophylaxis.
Known allergies.
Concomitant illnesses other than malaria.
Age and pregnancy.
Likely patient compliance with therapy.
Risk of re-exposure to malaria after treatment.
Choice of regimen is based on:(7)
-
8/10/2019 K25. Malaria pada Anak.ppt
38/39
References
1. White N. J. The treatment of malaria. The New England Journal of
Medicine, September 12, 1996, pp. 800-6.2. Making a difference. The Wold Health Report 1999. Health Millions
1999, 25(4), pp. 3-5.
3. Wolf J. E. Treatment and prevention of malaria: an update. Hospital
Physician, December 2002, pp. 15-22.
4. Davis, T. M. E. Malaria Treatment. (15/04/2003). .
5. Juckett, G. Malaria Prevention in Travelers. American Family Physicians
(8/01/2001). .
6. Bosman Andrea How to protect your self against malaria. GlobalMalaria Programme Geneva, 10 September 2008.
7. Kundu Ritabtata Management of Malaria in Children : Updated 2008
Infectious Diseases Chapter, Indian Academic of Pediatrics, Vol 45,
September 17, 2008.
-
8/10/2019 K25. Malaria pada Anak.ppt
39/39
TERIMA
KASIH